Efficacy Comparison of Targeted Systemic Monotherapies Including Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: a Network Meta-Analysis. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 8, n. 1, p. s313, 2024. DOI: 10.25251/skin.8.supp.313. Disponível em: https://skin.dermsquared.com/skin/article/view/2391. Acesso em: 17 may. 2025.